Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -16.79
- Piotroski Score 2.00
- Grade N/A
- Symbol (HUGE)
- Company FSD Pharma Inc.
- Price $0.09
- Changes Percentage (-10.1%)
- Change -$0.01
- Day Low $0.09
- Day High $0.10
- Year High $109.19
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.25
- Trailing P/E Ratio -0.94
- Forward P/E Ratio -0.94
- P/E Growth -0.94
- Net Income $-18,564,915
Income Statement
Quarterly
Annual
Latest News of HUGE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Billionaire Jeff Yass Sold 29% of Susquehanna's Stake in Nvidia and Is Piling Into Another Huge Artificial Intelligence (AI) Stock
The rise of AI investing trends post-2022, with projections of $15.7 trillion in global economic activity by 2030, has attracted Wall Street's attention....
By Yahoo! Finance | 19 hours ago -
Palantir Reaches Huge Milestone: Here's What Could Happen Next
Palantir (NYSE: PLTR) has outperformed Lockheed Martin in market cap, driven by strong revenue growth and profit increase. With a focus on government and enterprise sectors, Palantir's hypergrowth mom...
By Yahoo! Finance | 1 day ago -
The Elixir of Love review - Donizetti's romcom staged as second world war sitcom is hugely enjoyable
Harry Fehr's innovative staging of Donizetti's The Elixir of Love at the English National Opera transports the romantic comedy to England during WWII....
By The Guardian | 1 day ago
